Imaging serotonergic transmission with [11C]DASB-PET in depressed and non-depressed patients infected with HIV

INTRODUCTION Site-selective imaging can provide significant insight into the mechanism of HIV-associated neurological disease. The goal of this study was to evaluate the involvement of serotonergic transmission in HIV-associated depression using [(11)C]DASB, a serotonin transporter (5-HTT)-specific radiopharmaceutical for positron emission tomography (PET). METHODS Nine depressed HIV+ subjects (HIV-D), 9 non-depressed HIV+ subjects (HIV-ND) and 7 healthy controls (HC) underwent an MRI scan and a [(11)C]DASB-PET scan. The outcome measure was 5-HTT binding potential normalized to non-displaceable tissue radioligand (BP(ND)). RESULTS HIV-ND subjects had lower mean regional 5-HTT BP(ND) estimates across regions compared to HC, while HIV-D subjects demonstrated higher mean regional binding values than HIV-ND subjects in most regions. Prior to correction for the false discovery rate, HIV-ND had significantly lower BP(ND) values compared to HC subjects in two regions (insula and anterior cingulate) and all HIV+ patients had significantly lower binding than HC in all regions except for the midbrain, thalamus and pons. After correction for the false discovery rate, only the insula showed significantly lower binding in HIV+ subjects compared to HC (P<0.0045). Despite a significant difference in the duration of illness between the HIV-D and HIV-ND groups, there was no definite correlation between the duration of illness and BP(ND). CONCLUSION Lower [(11)C]DASB binding in HIV+ patients compared to HC may reflect serotonergic neuronal loss as a component of generalized HIV-associated neurodegeneration. Higher mean regional BP(ND) values in HIV-D compared to HIV-ND subjects could reflect increased density of 5-HTT, leading to increased clearance of serotonin from the synapse, which could account, in part, for symptoms of depression. The lack of correlation between duration of illness and binding argues against these findings being the result of differential neurodegeneration only. Our findings suggest a possible role for dysregulated serotonergic transmission in HIV-associated depression.

[1]  J. Kruse,et al.  Improving screening for mental disorders in the primary care setting by combining the GHQ-12 and SCL-90-R subscales. , 2001, Comprehensive psychiatry.

[2]  S. Rourke,et al.  The Impact of Neuropsychological Impairment and Depression on Health-Related Quality of Life in HIV-Infection , 2005, Journal of clinical and experimental neuropsychology.

[3]  Mark Slifstein,et al.  Effects of reduced endogenous 5‐HT on the in vivo binding of the serotonin transporter radioligand 11C‐DASB in healthy humans , 2005, Synapse.

[4]  M. Bousser.  Neuropsychiatric manifestations in , 2007 .

[5]  Hiroshi Ito,et al.  Relationship Between Neuroticism Personality Trait and Serotonin Transporter Binding , 2007, Biological Psychiatry.

[6]  Masanori Ichise,et al.  Serotonin Transporter Binding in Bipolar Disorder Assessed using [11C]DASB and Positron Emission Tomography , 2006, Biological Psychiatry.

[7]  J. McDaniel,et al.  Double‐blind comparison of fluoxetine and desipramine in the treatment of depressed women with advanced HIV disease: A pilot study , 1999, Depression and Anxiety.

[8]  W. Banks,et al.  Mechanisms of HIV type 1-induced cognitive impairment: evidence for hippocampal cholinergic involvement with overstimulation of the VIPergic system by the viral coat protein core. , 2002, AIDS research and human retroviruses.

[9]  Z. Szabo,et al.  Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings , 1998, The Lancet.

[10]  Klaus Wienhard,et al.  The ECAT HRRT: performance and first clinical application of the new high resolution research tomograph , 2000 .

[11]  Bengt Långström,et al.  Potential of [11C]DASB for measuring endogenous serotonin with PET: binding studies. , 2005, Nuclear medicine and biology.

[12]  Laura M. Bogart,et al.  Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. , 2000, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[13]  Sylvain Houle,et al.  Novel 5-HTTLPR Allele Associates with Higher Serotonin Transporter Binding in Putamen: A [11C] DASB Positron Emission Tomography Study , 2007, Biological Psychiatry.

[14]  John Hilton,et al.  as Serotonin Transporter Radioligands Under Various Experimental Conditions , 2002 .

[15]  J. Rothstein,et al.  Reduced expression of glutamate transporter EAAT2 and impaired glutamate transport in human primary astrocytes exposed to HIV-1 or gp120. , 2003, Virology.

[16]  S. Dursun,et al.  Serotonin hypothesis of psychiatric disorders during HIV infection. , 1995, Medical hypotheses.

[17]  T. Cooper,et al.  Hormone responses to fenfluramine and placebo challenge in endogenous depression , 1992, Psychiatry Research.

[18]  D. Cruess,et al.  Prevalence, diagnosis, and pharmacological treatment of mood disorders in HIV disease , 2003, Biological Psychiatry.

[19]  Alan A. Wilson,et al.  Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography , 2007, Psychopharmacology.

[20]  Jeih-San Liow,et al.  Linearized Reference Tissue Parametric Imaging Methods: Application to [11C]DASB Positron Emission Tomography Studies of the Serotonin Transporter in Human Brain , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[21]  David Goldman,et al.  Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain. , 2006, The American journal of psychiatry.

[22]  D. Cruess,et al.  90 NEUROPSYCHIATRIC MANIFESTATIONS OF HIV-1 INFECTION AND AIDS , 2002 .

[23]  N. Volkow,et al.  Decreased brain dopaminergic transporters in HIV-associated dementia patients. , 2004, Brain : a journal of neurology.

[24]  Jeih-San Liow,et al.  PET [11C]DASB imaging of serotonin transporters in patients with alcoholism. , 2007, Alcoholism, clinical and experimental research.

[25]  R. Vaughan.  High anxiety. , 1995, Nursing times.

[26]  D. Nutt,et al.  Acute Tryptophan Depletion. Part II: Clinical Effects and Implications , 2005 .

[27]  Lr Derogatis,et al.  SCL-90-R, Administration, Scoring, and Procedures Manual-II for the R(evised) Version and Other Instruments of the Psychopathology Rating Scale Series , 1983 .

[28]  C. Halldin,et al.  Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain , 2004, Human brain mapping.

[29]  P. Riederer,et al.  Dopamine deficits and regulation of the cAMP second messenger system in brains of simian immunodeficiency virus-infected rhesus monkeys , 2004, Journal of NeuroVirology.

[30]  Alan A. Wilson,et al.  Positron Emission Tomography Quantification of [11C]-DASB Binding to the Human Serotonin Transporter: Modeling Strategies , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[31]  R. Nosheny,et al.  Intrastriatal administration of human immunodeficiency virus-1 glycoprotein 120 reduces glial cell-line derived neurotrophic factor levels and causes apoptosis in the substantia nigra. , 2006, Journal of neurobiology.

[32]  Sylvain Houle,et al.  [11C]‐DASB, a tool for in vivo measurement of SSRI‐induced occupancy of the serotonin transporter: PET characterization and evaluation in cats , 2003, Synapse.

[33]  John E. Roberts,et al.  Meta-analysis of the relationship between HIV infection and risk for depressive disorders. , 2001, The American journal of psychiatry.

[34]  M. Kaul,et al.  Mechanisms of neuronal injury and death in HIV-1 associated dementia. , 2006, Current HIV research.

[35]  M Davies,et al.  The Structured Clinical Interview for DSM-III-R (SCID). II. Multisite test-retest reliability. , 1992 .

[36]  John Hilton,et al.  Comparison of (+)-11C-McN5652 and 11C-DASB as Serotonin Transporter Radioligands Under Various Experimental Conditions , 2002 .

[37]  G. Juckel,et al.  Functional Cortical Effects of Novel Allelic Variants of the Serotonin Transporter Gene-linked Polymorphic Region (5-HTTLPR) in Humans , 2007, Pharmacopsychiatry.

[38]  B. Gutiérrez,et al.  The 5‐HTTLPR s/s genotype at the serotonin transporter gene (SLC6A4) increases the risk for depression in a large cohort of primary care attendees: The PREDICT‐gene study , 2006, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[39]  Jung Bum Kim,et al.  Influence of the serotonin transporter promoter gene polymorphism on susceptibility to posttraumatic stress disorder , 2005, Depression and anxiety.

[40]  P. Riederer,et al.  Parkinsonism in HIV dementia , 2002, Journal of Neural Transmission.

[41]  J. Russo,et al.  Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone. , 1999, The Journal of clinical psychiatry.

[42]  D. Stoff,et al.  Workshop report: the effects of psychological variables on the progression of HIV-1 disease , 2004, Brain, Behavior, and Immunity.

[43]  Alan A. Wilson,et al.  The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. , 2001, The American journal of psychiatry.

[44]  Masanori Ichise,et al.  Elevated Serotonin Transporter Binding in Major Depressive Disorder Assessed Using Positron Emission Tomography and [11C]DASB; Comparison with Bipolar Disorder , 2007, Biological Psychiatry.

[45]  G. Juhász,et al.  High anxiety and migraine are associated with the s allele of the 5HTTLPR gene polymorphism , 2007, Psychiatry Research.

[46]  Richard E Carson,et al.  Noise Reduction in the Simplified Reference Tissue Model for Neuroreceptor Functional Imaging , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[47]  M. First,et al.  The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. , 1992, Archives of general psychiatry.

[48]  Time Course of In Vivo 5-HTT Transporter Occupancy by Fluvoxamine , 2006, Journal of clinical psychopharmacology.

[49]  N. Sacktor,et al.  Human immunodeficiency virus-associated dementia: An evolving disease , 2003, Journal of NeuroVirology.

[50]  J. Nurnberger,et al.  Early-emerging cognitive vulnerability to depression and the serotonin transporter promoter region polymorphism. , 2008, Journal of affective disorders.

[51]  A. Heinz,et al.  Midbrain serotonin transporter binding potential measured with [11C]DASB is affected by serotonin transporter genotype , 2007, Journal of Neural Transmission.

[52]  Ramin V. Parsey,et al.  Acute Occupancy of Brain Serotonin Transporter by Sertraline as Measured by [11C]DASB and Positron Emission Tomography , 2006, Biological Psychiatry.

[53]  S. Kéri,et al.  Major depressive disorder, serotonin transporter, and personality traits: why patients use suboptimal decision-making strategies? , 2007, Journal of affective disorders.

[54]  D. Nutt,et al.  Acute Tryptophan Depletion. Part I: Rationale and Methodology , 2005, The Australian and New Zealand journal of psychiatry.

[55]  T. Jernigan,et al.  Progressive cerebral volume loss in human immunodeficiency virus infection: a longitudinal volumetric magnetic resonance imaging study. HIV Neurobehavioral Research Center Group. , 1998, Archives of neurology.

[56]  Sylvain Houle,et al.  Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region? , 2005, Nuclear medicine and biology.

[57]  Zsolt Szabo,et al.  Quantitative PET Studies of the Serotonin Transporter in MDMA Users and Controls Using [11C]McN5652 and [11C]DASB , 2005, Neuropsychopharmacology.

[58]  Sylvain Houle,et al.  Effects of Tryptophan Depletion on the Serotonin Transporter in Healthy Humans , 2005, Biological Psychiatry.

[59]  Sylvain Houle,et al.  In vitro and in vivo characterisation of [11C]-DASB: a probe for in vivo measurements of the serotonin transporter by positron emission tomography. , 2002, Nuclear medicine and biology.

[60]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[61]  A. Wu,et al.  Depression Is a Risk Factor for Suboptimal Adherence to Highly Active Antiretroviral Therapy , 2002, Journal of acquired immune deficiency syndromes.

[62]  J. Rabkin,et al.  Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. , 1999, The American journal of psychiatry.

[63]  Mark Slifstein,et al.  Estimation of serotonin transporter parameters with 11C-DASB in healthy humans: reproducibility and comparison of methods. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[64]  H. Furr,et al.  [Metabolism and function of vitamin A]. , 1985, Archives francaises de pediatrie.

[65]  R. Salomon,et al.  Acute tryptophan depletion , 1992 .

[66]  P. Knekt,et al.  Randomized trial on the effectiveness of long-and short-term psychodynamic psychotherapy and solution-focused therapy on psychiatric symptoms during a 3-year follow-up , 2007, Psychological Medicine.

[67]  M. Cao,et al.  Study on the interrelationship between 5-HTTLPR/G-protein &bgr;3 subunit (C825T) polymorphisms and depressive disorder , 2007, Psychiatric genetics.

[68]  Jeffrey H Meyer,et al.  Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. , 2007, Journal of psychiatry & neuroscience : JPN.

[69]  J. Russo,et al.  Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients. , 1998, The American journal of psychiatry.

[70]  W. van den Brink,et al.  Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"): preliminary findings. , 2001, Archives of general psychiatry.

[71]  J. Caballero,et al.  Use of Selective Serotonin-Reuptake Inhibitors in the Treatment of Depression in Adults with HIV , 2005, The Annals of pharmacotherapy.

[72]  D. Cruess,et al.  Neuropsychopharmacologic Treatment of Depression and Other Neuropsychiatric Disorders in HIV-Infected Individuals , 2003, CNS Spectrums.

[73]  J. Berman,et al.  Neuroimmunity and the Blood–Brain Barrier: Molecular Regulation of Leukocyte Transmigration and Viral Entry into the Nervous System with a Focus on NeuroAIDS , 2006, Journal of Neuroimmune Pharmacology.

[74]  Sylvain Houle,et al.  Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. , 2004, Archives of general psychiatry.

[75]  M. Holi,et al.  A Finnish validation study of the SCL‐90 , 1998, Acta psychiatrica Scandinavica.

[76]  Ronald Boellaard,et al.  HRRT Versus HR+ Human Brain PET Studies: An Interscanner Test–Retest Study , 2009, Journal of Nuclear Medicine.

[77]  Masanori Ichise,et al.  PET imaging of serotonin transporters with [11C]DASB: test-retest reproducibility using a multilinear reference tissue parametric imaging method. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[78]  S. Tanada,et al.  A dose-finding study of duloxetine based on serotonin transporter occupancy , 2006, Psychopharmacology.

[79]  M. Otto,et al.  Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring. , 2001, Behaviour research and therapy.

[80]  L. Hurley,et al.  Effects of Depression and Selective Serotonin Reuptake Inhibitor Use on Adherence to Highly Active Antiretroviral Therapy and on Clinical Outcomes in HIV-Infected Patients , 2008, Journal of acquired immune deficiency syndromes.

[81]  G. Cordero.  [HIV infection]. , 1995, SIDAhora : un proyecto del Departamento de Publicaciones del PWA Coalition, NY.

[82]  L. Derogatis,et al.  Symptom Checklist-90–Revised , 2011 .

[83]  A. Llerena,et al.  Increased risk for major depression associated with the short allele of the serotonin transporter promoter region (5‐HTTLPR‐S) and the CYP2C9*3 allele , 2007, Fundamental & clinical pharmacology.

[84]  K. Ng,et al.  HIV-1 protein gp120 rapidly impairs memory in chicks by interrupting the glutamate–glutamine cycle , 2007, Neurobiology of Learning and Memory.

[85]  S. Kalichman,et al.  Continued high-risk sex among HIV seropositive gay and bisexual men seeking HIV prevention services. , 1997, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[86]  P. Cowen,et al.  5-HTT binding in recovered depressed patients and healthy volunteers: a positron emission tomography study with [11C]DASB. , 2007, The American journal of psychiatry.

[87]  A. Meyer-Lindenberg,et al.  5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression , 2005, Nature Neuroscience.